ZA200707953B - Methods and compositions for modulating hyperstabilized c-met - Google Patents

Methods and compositions for modulating hyperstabilized c-met

Info

Publication number
ZA200707953B
ZA200707953B ZA200707953A ZA200707953A ZA200707953B ZA 200707953 B ZA200707953 B ZA 200707953B ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 A ZA200707953 A ZA 200707953A ZA 200707953 B ZA200707953 B ZA 200707953B
Authority
ZA
South Africa
Prior art keywords
hyperstabilized
modulating
met
compositions
methods
Prior art date
Application number
ZA200707953A
Other languages
English (en)
Inventor
Kong-Beltran Monica
Dineli M Wickramasinghe
Original Assignee
Genenthech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37053941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200707953(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genenthech Inc filed Critical Genenthech Inc
Publication of ZA200707953B publication Critical patent/ZA200707953B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200707953A 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met ZA200707953B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66548205P 2005-03-25 2005-03-25

Publications (1)

Publication Number Publication Date
ZA200707953B true ZA200707953B (en) 2009-06-24

Family

ID=37053941

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200707953A ZA200707953B (en) 2005-03-25 2006-03-24 Methods and compositions for modulating hyperstabilized c-met

Country Status (18)

Country Link
US (2) US7615529B2 (ja)
EP (1) EP1868648B1 (ja)
JP (2) JP2008535821A (ja)
KR (1) KR20080000613A (ja)
CN (1) CN101184506B (ja)
AU (1) AU2006229989B2 (ja)
BR (1) BRPI0611468A2 (ja)
CA (1) CA2599988A1 (ja)
ES (1) ES2539790T3 (ja)
HK (1) HK1109075A1 (ja)
IL (1) IL185708A (ja)
MX (1) MX2007011652A (ja)
NO (1) NO20075412L (ja)
NZ (1) NZ561211A (ja)
RU (1) RU2404193C2 (ja)
SG (1) SG159547A1 (ja)
WO (1) WO2006104911A2 (ja)
ZA (1) ZA200707953B (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1868648B1 (en) * 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
US20090226443A1 (en) * 2008-03-06 2009-09-10 Genentech, Inc. Combination therapy with c-met and egfr antagonists
EP2370467B1 (en) * 2008-10-01 2016-09-07 Amgen Research (Munich) GmbH Cross-species-specific pscaxcd3, cd19xcd3, c-metxcd3, endosialinxcd3, epcamxc d3, igf-1rxcd3 or fapalpha xcd3 bispecific single chain antibody
PA8849001A1 (es) 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
CA2757531A1 (en) * 2009-04-07 2010-10-14 Roche Glycart Ag Bispecific anti-erbb-3/anti-c-met antibodies
JP5612663B2 (ja) * 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
NZ595792A (en) 2009-04-20 2014-01-31 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
KR101671378B1 (ko) * 2009-10-30 2016-11-01 삼성전자 주식회사 ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그의 용도
SI2496601T1 (sl) 2009-11-05 2017-09-29 F. Hoffmann-La Roche Ag Tehnike in sestavek za sekrecijo heterolognih polipeptidov
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
KR20130138802A (ko) * 2010-10-20 2013-12-19 옥스포드 바이오테라퓨틱스 리미티드 항체
CA2835242A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
US9201074B2 (en) 2011-09-20 2015-12-01 Eli Lilly And Company Anti-c-Met antibodies
WO2013049112A1 (en) * 2011-09-27 2013-04-04 Emory University Detection of biomarkers using magnetic resonance
KR20130036993A (ko) 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
CA2854477A1 (en) * 2011-11-21 2013-05-30 Genentech, Inc. Purification of anti-c-met antibodies
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10260089B2 (en) 2012-10-29 2019-04-16 The Research Foundation Of The State University Of New York Compositions and methods for recognition of RNA using triple helical peptide nucleic acids
EP2727941A1 (en) 2012-11-05 2014-05-07 MAB Discovery GmbH Method for the production of multispecific antibodies
WO2014067642A1 (en) 2012-11-05 2014-05-08 Mab Discovery Gmbh Method for the production of multispecific antibodies
KR20150143458A (ko) 2013-03-06 2015-12-23 메리맥 파마슈티컬즈, 인크. 항-C-MET 탠덤 Fc 이중특이적 항체
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
MA39746A (fr) 2014-03-14 2021-04-28 Hoffmann La Roche Compositions de sécrétion de polypeptides hétérologues et procédés associés
MA39776A (fr) 2014-03-24 2017-02-01 Hoffmann La Roche Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
EP3193940A1 (en) 2014-09-10 2017-07-26 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
MX2017003211A (es) 2014-09-16 2017-06-06 Symphogen As Anticuerpos anti-met y composiciones.
GB201419108D0 (en) * 2014-10-27 2014-12-10 Glythera Ltd Materials and methods relating to linkers for use in antibody drug conjugates
KR20170136536A (ko) 2015-03-16 2017-12-11 셀덱스 쎄라퓨틱스, 인크. 항-met 항체 및 그 사용 방법
KR102561356B1 (ko) 2016-09-14 2023-08-03 애브비 바이오테라퓨틱스 인크. 항-pd-1 항체 및 이의 용도
CN109862919A (zh) 2016-10-11 2019-06-07 免疫医疗有限公司 抗体-药物缀合物联合免疫介导的治疗剂
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
EP3796942A1 (en) 2018-05-23 2021-03-31 ADC Therapeutics SA Molecular adjuvant
MX2021000421A (es) 2018-07-15 2021-05-12 Enochian Biopharma Inc Métodos y composiciones que usan células dendríticas recombinantes para el tratamiento del cáncer.
WO2020174370A2 (en) 2019-02-26 2020-09-03 Janssen Biotech, Inc. Combination therapies and patient stratification with bispecific anti-egfr/c-met antibodies
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
JP2022547274A (ja) 2019-09-16 2022-11-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
CN114478788A (zh) 2020-11-11 2022-05-13 高新 一种同时靶向cd3和cd137的融合蛋白及其制备方法和用途
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP2014772A3 (en) 1996-04-05 2009-05-27 Antonio Giordano Method for the diagnosis and prognosis of cancer
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
AU2003230874A1 (en) * 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP1592713A2 (en) 2003-02-13 2005-11-09 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
KR20110117728A (ko) * 2003-06-06 2011-10-27 제넨테크, 인크. Ｈｇｆ 베타 쇄와 ｃ-ｍｅｔ 사이의 상호작용의 변조
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
AU2004298483A1 (en) * 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
ZA200604864B (en) 2003-12-19 2007-10-31 Genentech Inc Monovalent antibody fragments useful as therapeutics
EP1868648B1 (en) 2005-03-25 2015-04-15 Genentech, Inc. Methods and compositions for modulating hyperstabilized c-met
AU2006229990A1 (en) 2005-03-25 2006-10-05 Genentech, Inc. C-met mutations in lung cancer

Also Published As

Publication number Publication date
MX2007011652A (es) 2007-11-14
NZ561211A (en) 2011-03-31
US7615529B2 (en) 2009-11-10
HK1109075A1 (en) 2008-05-30
WO2006104911A3 (en) 2007-02-22
SG159547A1 (en) 2010-03-30
EP1868648A2 (en) 2007-12-26
US20100028337A1 (en) 2010-02-04
AU2006229989B2 (en) 2012-02-02
JP2008535821A (ja) 2008-09-04
US20060270594A1 (en) 2006-11-30
JP2012232979A (ja) 2012-11-29
KR20080000613A (ko) 2008-01-02
NO20075412L (no) 2007-12-21
RU2007139452A (ru) 2009-04-27
EP1868648B1 (en) 2015-04-15
RU2404193C2 (ru) 2010-11-20
US8536118B2 (en) 2013-09-17
ES2539790T3 (es) 2015-07-06
AU2006229989A1 (en) 2006-10-05
CN101184506B (zh) 2013-07-17
WO2006104911A2 (en) 2006-10-05
IL185708A (en) 2014-11-30
CA2599988A1 (en) 2006-10-05
CN101184506A (zh) 2008-05-21
BRPI0611468A2 (pt) 2010-09-08
IL185708A0 (en) 2008-01-06

Similar Documents

Publication Publication Date Title
IL185708A0 (en) Methods and compositions for modulating hyperstabilized c-met
EP1895838A4 (en) COMPOSITIONS AND METHODS
GB0522658D0 (en) Composition
HK1165444A1 (zh) 用於調整止血的組合物及方法
EP1843734A4 (en) COMPOSITIONS AND METHOD FOR INTENSIFYING COGNITIVE FUNCTIONS
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
EP1962852A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
GB0519164D0 (en) Composition
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) hair dye
GB0507167D0 (en) Composition
IL185753A0 (en) Methods and compositions for modulating vascular integrity
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0501348D0 (en) Compositions and methods
GB0502341D0 (en) Composition
EP1924257A4 (en) STABILIZED 3-HYDROXYFLAVAN COMPOSITIONS AND METHOD THEREFOR
GB0513641D0 (en) Anti-egeing composition
EP1809761A4 (en) COMPOSITIONS AND METHODS FOR MODULATING DHR96
GB0510286D0 (en) Composition
GB0525968D0 (en) Compositions and methods
GB0508963D0 (en) Composition
GB0515477D0 (en) Composition
GB0523760D0 (en) Composition